SY17-3 Current status and perspective of the combination of immunotherapy and chemoradiotherapy for locally advanced head and neck cancer

Abstract

The standard treatment for locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) is surgery ± postoperative (chemo)radiation therapy [(C)RT] or definitive CRT. The standard concurrent chemotherapy regimen is tri-weekly cisplatin. In the postoperative setting, weekly cisplatin is an alternative option. For laryngeal preservation, induction docetaxel, cisplatin, and 5-FU followed by (C)RT is the treatment option. Recently, the efficacy of combined immunotherapy and CRT for curative intent has been reported.